‘Although a minority of donors displayed the AA genotype , this gene variant nevertheless shows potential in identifying a subpopulation at higher threat of allograft failure, and additional investigation of its part in the etiology of renal fibrosis could be warranted,’ the authors write. ‘This finding provides implications for renal transplantation with regard to the mechanisms underlying graft failure and in the identification of genetic biomarkers. Furthermore, because renal transplantation might be considered an in vivo model of accelerated tissue fibrosis, this study may have relevance for additional renal and nonrenal diseases seen as a tissue fibrosis. Finally, this study may also possess implications for other conditions in which CAV1 is considered to play a part, in particular vascular neoplasia and disease.’..It gets the potential to standardise handover across medical center trusts in the U.K.T. Interface. For more information about eHandover and how it can improve your medical handover, please reserve a accepted place at the Clinical Handover conference or contact Ascribe.

Merck and Bionomics Serono to collaborate to find and develop novel, oral medication for MS Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today a Development and Licensing Contract with Bionomics was signed announced, under which Merck Serono would develop new remedies for multiple sclerosis and other autoimmune circumstances based on substances from Bionomics Kv1.3 program.